Key Takeaways DGX posted strong Q1 growth across brain health, oncology and women's health diagnostics. Strategic deals like LifeLabs and PathAI Diagnostics strengthen DGX's core and adjacent markets. DGX targets 3% annual cost savings with automation, Project Nova and GenAI partnerships.Quest Diagnostics Inc. (DGX) is investing in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. The company’s growth strategy includes pursuing value-creating, strate ...

With women’s health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women’s health diagnostics market to expand at a compound annual rate of 9.25% through 2030, driven by technological advancements, increasing healthcare expenditures, and initiatives for early detection of women-specific conditions like reproductive health issues, breast cancer, osteoporosis and more. Two U.S. healthcare ...

Core Insights - The report titled "The Cancer Paradox" reveals that oncologists are increasingly encountering advanced-stage cancers, attributing this trend primarily to screening barriers and other factors [3][4][5] - The report highlights the need for improved post-treatment monitoring tools, particularly the emerging ctDNA minimal residual disease (MRD) blood tests, which could enhance early detection of cancer recurrence [3][4][8] Group 1: Oncologists' Perspectives - 76% of oncologists report seeing more advanced-stage cancers, with 75% citing screening barriers as the main cause, followed by aging population (48%) and lifestyle factors (43%) [4][5] - 68% of oncologists believe missed or delayed follow-up care is a significant reason for missed cancer recurrence, while 50% point to imaging tests failing to detect recurrence early enough [5][13] - 94% of oncologists agree that ctDNA MRD testing could reduce delays in diagnosing cancer recurrence, although they face barriers to its widespread adoption [5][8] Group 2: Limitations of Current Monitoring Methods - Traditional methods for monitoring cancer recurrence, such as PET scans and MRIs, are viewed as expensive and invasive, with 50% of oncologists noting that imaging tests often fail to detect recurrence early [6][7] - Nearly all oncologists (96%) believe MRD testing can identify cancer recurrence earlier than current methods, with 89% emphasizing the importance of test sensitivity [7][8] Group 3: Adoption of ctDNA MRD Testing - 88% of oncologists support incorporating MRD testing into standard care for cancer-recurrence monitoring, but over half would be more inclined to recommend it with more clinical evidence, inclusion in clinical guidelines, and better insurance coverage [8][9] - A study published in NEJM found that the Haystack MRD test was a reliable alternative to tissue biopsies, identifying complete responses to immunotherapy faster than traditional imaging methods [9] Group 4: Oncologists' Challenges - 89% of oncologists believe early detection of cancer recurrence can improve outcomes, yet 79% report seeing patients whose recurrence was missed at earlier stages [13] - Anxiety and worry are cited as significant challenges for patients, with 87% of oncologists acknowledging this concern, compared to 53% who mention treatment side effects [13]

Quest Diagnostics (DGX) Q1 2025 Earnings Call April 22, 2025 08:30 AM ET Company Participants Shawn Bevec - VP of IRJames Davis - Chairman, CEO & PresidentSam Samad - Executive VP & CFOKevin Caliendo - Managing DirectorPatrick Donnelly - Managing DirectorNoah Kava - Equity Research AssociateMichael Ryskin - Managing Director Conference Call Participants Luke Sergott - AnalystElizabeth Anderson - AnalystMichael Cherny - Senior Managing Director & Senior Research AnalystPito Chickering - AnalystDavid Westenbe ...